---
title: "316 Growth-stage Healthtech Investors (Nov 2026)"
last_updated: "2026-11-09"
rows: "316"
free_rows: "25"
source: "SEC Form D filings and our own research"
canonical: "https://theinvestordatabase.com/lists/growth-healthtech-investors/"
---

# 316 growth-stage healthtech investors

We list 316 growth-stage healthtech investors as of November 2026: 121 have an SEC filing on file and 195 were checked on the firm's own website or an official register, and the list was last checked on 9 Nov 2026. The states with the most are California (30), New York (21) and Massachusetts (12).

- 316 investors
- 133 with a fund filing or dated deal in the last 12 months
- $106M median fund size on file (SEC Form D, 79 firms)
- 1,525 named decision-makers on file

## First 25 of 316 growth-stage healthtech investors

| Investor | Type | HQ | Stages (our research) | Focus (our research) | Latest fund or deal | Fund size | Checked | Profile |
|---|---|---|---|---|---|---|---|---|
| Bullhound Capital | VC firm | London, United Kingdom | Growth | Healthtech, AI, Quantum, Robotics | New deal, Oct 2026 | €1.0B (own site) | 2026-11-05 | https://theinvestordatabase.com/investors/bullhound-capital/ |
| Transformation Capital | VC firm | Boston, MA | Growth | Healthtech, Medtech | New fund, Sep 2026 | $800M (SEC Form D, 2022) | 2026-11-04 | https://theinvestordatabase.com/investors/transformation-capital/ |
| MS+PARTNERS | Fund manager | London, United Kingdom | Growth | Healthtech, Industrial Tech, Energy, Climate Tech | New fund, Sep 2026 | €300M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/ms-partners/ |
| Echo Health Ventures | Corporate VC | Durham, NC | Growth | Healthtech, Medtech | Portfolio news, Sep 2026 | $518M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/echo-health-ventures/ |
| NewVale Capital | VC firm | Boulder, CO | Growth | Healthtech, Biotech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/newvale-capital/ |
| Town Hall Ventures | VC firm | New York, NY | Growth | Healthtech, Impact, Medtech | New deal, Sep 2026 | $400M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/town-hall-ventures/ |
| Quartus | VC firm | New York, NY | Growth | Healthtech, AI, B2B, Edtech | New fund, Sep 2026 | $150M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/quartus/ |
| Audere | VC firm | Austin, TX | Growth | Healthtech, Cybersecurity, AI, Robotics | New fund, Oct 2026 | $100M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/audere/ |
| JSTAR Capital | VC firm | Austin, TX | Growth | Healthtech, AI, Fintech, Medtech | New fund, Aug 2026 | $100M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/jstar-capital/ |
| HLM Investment Partners | VC firm | Waltham, MA | Growth | Healthtech, Medtech | New fund, Aug 2026 | $61M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/hlm-investment-partners/ |
| Lauxera Capital Partners | VC firm | Paris, France | Growth | Healthtech, Medtech | New fund, May 2026 | €800M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/lauxera-capital-partners/ |
| Arcventis Health Partners | VC firm | New York, NY | Growth | Healthtech, Biotech, Medtech | New fund, Sep 2026 | $33M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/arcventis-health-partners/ |
| Highland Europe | VC firm | London, United Kingdom | Growth | Healthtech, AI, Cybersecurity, SaaS | New fund, Jul 2026 | €1.1B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/highland-europe/ |
| Innovation Industries | VC firm | Amsterdam, Netherlands | Series A, Series B, Growth | Healthtech, Deep Tech, AI, Food and Beverage | New fund, Oct 2026 | €1.0B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/innovation-industries-capital-partners-b-v/ |
| FTV Capital | VC firm | San Francisco, CA | Growth | Healthtech, Fintech, SaaS, B2B | New fund, Jul 2026 | $11.9B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/ftv-capital/ |
| Gresham House Ventures | VC firm | London, United Kingdom | Series A, Growth | Healthtech, AI, Marketing Tech, Fintech | New deal, Sep 2026 | £200M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/gresham-house-ventures/ |
| Claret Capital Partners | Venture debt | London, United Kingdom | Series B, Growth, Late stage | Healthtech, Biotech, Climate Tech, SaaS | New deal, Oct 2026 | €575M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/claret-capital-partners/ |
| Salica Investments | Fund manager | London, United Kingdom | Seed, Series A, Growth | Healthtech, Fintech, AI, Climate Tech | Portfolio news, Oct 2026 | £760M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/salica/ |
| PXN Ventures | Fund manager | Manchester, United Kingdom | Pre-seed, Seed, Series A, Growth | Healthtech, Generalist, SaaS, Deep Tech | Portfolio news, Nov 2026 | £760M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/pxn-ventures/ |
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Healthtech, Biotech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/longitude-venture-partners/ |
| Alpha Partners | VC firm | New York, NY | Series B, Growth | Healthtech, AI, Developer Tools, Cybersecurity | New fund, Oct 2026 | $200M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/alpha-partners/ |
| Mercia Asset Management | Fund manager | Henley-in-Arden, United Kingdom | Seed, Series A, Growth | Healthtech, Future of Work, AI, SaaS | Portfolio news, Oct 2026 | £400M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/mercia/ |
| The FSE Group | Fund manager | Fleet, United Kingdom | Seed, Series A, Growth | Healthtech, Generalist, Climate Tech, SaaS | Portfolio news, Sep 2026 | £395M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/the-fse-group/ |
| Cambridge Innovation Capital | VC firm | Cambridge, United Kingdom | Seed, Series A, Growth | Healthtech, Biotech, AI, Fintech | New fund, Oct 2026 | £600M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/cambridge-innovation-capital/ |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Healthtech, Edtech, Developer Tools, Mobility | Portfolio news, Oct 2026 | £3.0B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/bgf/ |

You are seeing 25 of 316. The full list adds 291 more investors and 1,525 named decision-makers.

Get all 316 investors and 1,525 named contacts, $297, one-time: https://theinvestordatabase.com/buy/bundle
This page: https://theinvestordatabase.com/lists/growth-healthtech-investors/

## Method and limits
- Source: 121 of the 316 rows carry an SEC filing (Form D or Form ADV). All 316 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule: Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states healthtech and digital health as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at growth-stage.
- Order: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Fill rates: Of 316 rows: stage 316, sector 316, fund size 196, website 316. In the paid file: named decision-makers on 282 rows, firm email on 173, LinkedIn page on 210, check size on 92.

## Questions
### How many growth-stage healthtech investors are there?
We list 316 as of November 2026. 133 of the 316 have a fund filing or a dated deal in the last 12 months.

### Which growth-stage healthtech investors raised a new fund in the last 12 months?
45 of the 316 have a fund filing dated in the last 12 months. The most recent on this list are Audere (Oct 2026), IVP: Venture capital for the Exceptional (Oct 2026) and K5 Global (Oct 2026).

### What is the typical fund size of growth-stage healthtech investors?
The median fund size on file for this list is $106M, across the 79 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 237 do not disclose a size there.

### How do I contact growth-stage healthtech investors?
The paid file holds 1,525 named decision-makers across 282 of these 316 and a firm email for 173. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.

### Where does the data on growth-stage healthtech investors come from?
121 of the 316 rows have an SEC filing on file (Form D or Form ADV) and 195 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 9 Nov 2026 at the latest. The whole file is re-verified twice a year.